"Expanding Beyond Blood Disorders
to Rare and Intractable Disease Treatments"

SK Plasma has expanded its portfolio to include treatments for rare and severe blood disorders.


On August 3, SK Plasma announced that it will begin supplying 'Revolpak Tablets 25·50mg', which received product approval from the Ministry of Food and Drug Safety in May, to the domestic market in earnest.


SK Plasma thrombocytopenia treatment 'Revolpak Tablets'. SK Plasma

SK Plasma thrombocytopenia treatment 'Revolpak Tablets'. SK Plasma

View original image

Revolpak is a prescription thrombocytopenia treatment containing eltrombopag olamine. Eltrombopag olamine works by promoting platelet production in the bone marrow to increase platelet count, and it is used in the treatment of chronic immune thrombocytopenia and severe aplastic anemia.


SK Plasma has expanded its portfolio of treatments for rare and severe blood disorders to include not only hemophilia therapies but also Revolpak, leveraging its accumulated expertise and supply capabilities in the field of blood products. The company stated that it will continue to secure and supply essential medications for patient care moving forward.



Kim Seungjoo, CEO of SK Plasma, stated, "Even if the number of patients is small, every new treatment option is important for those who need therapies for rare and intractable diseases. Based on our expertise in the field of blood disorders, we will broaden patient choices within blood-related therapeutics and expand our business into all areas of rare and intractable diseases where treatments have yet to be developed."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing